Benign Prostatic Hyperplasia (BHP) and Prostate Cancer
BHP can be dubbed as the non-cancerous increase in the size of the prostate, which occurs along the transition zone of the prostate. According to Allins (2010), comparison of Prostate Cancer, and BHP, the later is caused by increased levels of testosterone. It involves growth in the cell count (hyperplasia) rather than the growth of individual cell sizes (hypertrophy). As the cells grow in number, the prostate grows larger making the urethra narrower, and therefore increasing the resistance to the flow of urine (Collin, 2011). If this obstruction is sustained and not treated, the bladder is forced to put in more effort during voiding which may later cause complications such as chronic kidney diseases and bladder stones. The condition may eventually cause renal failure.
Prostate cancer, on the other hand, results from the growth of individual cells (Ruddon & Raymond, 2007). The cancer cells may eventually spread and affect other parts of the body. In later stages, Prostate Cancer might present symptoms such as urinating difficulties, blood clots in unrine, ache when urinating and lethargy owing to reduced number of red blood cells.
The Presentation Difference
The appearance of BHP can be more abrupt since the increase in the number of cell count is fast and more pronounced. The disorder is noticeable after a short period, but it will be necessary to consult a doctor first for testing and screening to affirm that it is indeed BHP (Ruddon & Raymond, 2007). However, the presentation of Prostate cancer will not be noticeable until the cancerous cells have fully matured and enlarged. The symptoms may appear at a later time but, as stated above, consultation with a medical officer will confirm that it is Prostate Cancer (Cunningham & Kadmon, 2013).
The Significance of the PSA Testing in the Patients
Both prostate cancer and BHP have more similarities than differences, and their symptoms seem to match, which are hard to notice. Collin (2011) assert that the PSA is a test, which screens for any Prostate Specific Antigen in the blood. Both BHA and Prostate Cancer cells produce the PSA protein, mostly, found in semen and circulate within the blood in small amounts (Ruddon & Raymond, 2007). The PSA test predicts the level of Prostate cancer achieved to initiate treatment plans for the affected patients.
Difference between Benign Prostatic Hyperplasia (BHP) and Prostate Cancer
Cunningham and Kadmon (2013) explain that prostate Cancer is one of the most common male cancer. It can be hard to identify it because it’s symptoms compare much to those of BHP, but according to Comparison of Prostate Cancer and BHP, some of the common ones are; numerous urination cycle mostly during the night and hesitation. The obstruction of urine, in this case, does not occur until when the cancerous cells have become advanced in their growth (Ruddon & Raymond, 2007).
On the other side, BHP becomes common to men above the age of 40 years, and the condition is the most common cause of urinary tract obstruction (Cunningham & Kadmon, 2013). The condition, as stated, bears similar symptoms with Prostate cancer but in the case of BHP, the conditions may occur in early stages as opposed to Prostate cancer where the symptoms may only be visible once the cancer cells have developed.
In the case of Prostate Cancer, once the stage of the disease is known, it depends entirely on the infected party for which program will be most suitable for them (Treating Prostate Cancer) (Cunningham & Kadmon, 2013). The most commonly practiced plans are surgery, radiotherapy, hormone therapy, vaccine treatment and chemotherapy. For BHP, maintenance plans include physical exercise, reducing intake of drinks and fluids before bedtime, use of medication such as alpha blockers and 5-alpha reductase inhibitors and surgery.
Allins, J. (2010). Comparison of Prostate Cancer and BHP obtained from
Collin, H. (2011). Treating Prostate Cancer got from https://www.cancer.org/cancer/prostate-cancer/treating.html
Cunningham GR, Kadmon D (2013) Epidemiology and pathogenesis of benign prostatic hyperplasia.
Ruddon, Raymond W. (2007). Cancer Biology (4th ed.). Oxford: Oxford University Press.